Is Psilocybin Legal? State-by-State Guide for 2026
The legal landscape surrounding psilocybin in the United States is undergoing a profound transformation, marked by a dynamic interplay of federal prohibition, state-level legalization, and local decriminalization efforts. As of 2026, understanding the nuances of these regulations is crucial for anyone interested in the therapeutic or personal use of psilocybin-containing mushrooms. This guide provides a comprehensive overview of the current legal status, highlighting key developments and what to expect in the coming years.
Federal Status: A Persistent Schedule I Classification
Despite the growing momentum for reform, psilocybin remains classified as a Schedule I controlled substance under federal law, a designation it shares with drugs like heroin and LSD [1]. This classification, established by the Controlled Substances Act (CSA) of 1970, signifies that the federal government views psilocybin as having a high potential for abuse and no currently accepted medical use [2]. Consequently, federal prosecution for the possession, sale, or cultivation of psilocybin is theoretically possible anywhere in the U.S. However, in practice, federal enforcement against personal-use psilocybin possession has been exceedingly rare, with the Drug Enforcement Administration (DEA) indicating that such cases are not a primary focus [3].
The federal stance, while seemingly rigid, is not entirely static. The U.S. Food and Drug Administration (FDA) has granted two breakthrough therapy designations for psilocybin: one in 2018 for treatment-resistant depression and another in 2019 for major depressive disorder [4]. These designations accelerate the development and review of drugs that show substantial improvement over existing therapies for serious conditions. Biotechnology companies, such as Compass Pathways, are in advanced stages of clinical trials for synthetic psilocybin (COMP360) for treatment-resistant depression, with new drug applications anticipated between late 2026 and 2027 [5]. Should the FDA approve psilocybin for medical use, it would necessitate a reevaluation of its Schedule I status, potentially leading to federal rescheduling and a significant shift in national policy.
State-Level Legalization: Oregon and Colorado Lead the Way
Oregon and Colorado have emerged as pioneers in establishing regulated psilocybin access programs, offering models for other states considering similar reforms. These states have moved beyond mere decriminalization to create comprehensive frameworks for supervised psilocybin therapy.
Oregon: Measure 109 and Supervised Psilocybin Services
In 2020, Oregon voters passed Measure 109, which established a legal framework for supervised psilocybin services. This landmark initiative allows adults aged 21 and older to access psilocybin in licensed service centers under the guidance of trained and state-licensed facilitators [6]. The first licensed service centers began operating in 2023, providing a regulated environment for individuals seeking psilocybin-assisted therapy. The Oregon Health Authority oversees the program, ensuring safety, training standards, and equitable access.
Colorado: Proposition 122 and Natural Medicine Health Act
Following Oregon\\'s lead, Colorado voters approved Proposition 122 in 2022, creating a similar framework for regulated access to natural medicines, including psilocybin. This legislation permits the establishment of licensed healing centers where adults 21 and over can receive supervised psilocybin sessions [7]. Additionally, Proposition 122 allows for the personal cultivation and sharing (without remuneration) of psilocybin for adults 21+, marking a significant step towards broader access. Licensed healing centers in Colorado began operating in 2024, further expanding the availability of supervised psilocybin experiences.
The Rise of Decriminalization: A City-by-City Movement
Beyond state-level initiatives, a growing number of cities across the U.S. have adopted policies to decriminalize psilocybin. Decriminalization does not equate to legalization; rather, it reclassifies offenses related to personal possession of psilocybin as the lowest law enforcement priority, often resulting in reduced penalties or no arrests [8]. This movement reflects a shift in public perception and a recognition of the potential benefits of psychedelics.
Key Cities with Decriminalization Policies:
- Denver, CO (2019): The first U.S. city to decriminalize psilocybin through a ballot initiative.
- Oakland, CA (2019): Decriminalized all naturally occurring psychedelics, including psilocybin.
- Santa Cruz, CA (2020): Followed Oakland\\'s lead in decriminalizing natural psychedelics.
- Washington D.C. (2020): Voters approved Initiative 81, decriminalizing entheogenic plants and fungi.
- Ann Arbor, MI (2020): City council passed a resolution decriminalizing entheogenic plants.
- Seattle, WA (2021): Decriminalized the cultivation and possession of natural psychedelics.
- Detroit, MI (2021): Voters approved a ballot initiative to decriminalize entheogenic plants.
While decriminalization offers a degree of protection, it is essential to understand that federal law still applies, and individuals in these cities could theoretically face federal charges. However, local law enforcement agencies typically prioritize other offenses, making federal intervention unlikely for personal use.
Understanding the Nuances: Decriminalization vs. Legalization
The terms \"decriminalization\" and \"legalization\" are often used interchangeably, but they represent distinct legal statuses with different implications. Legalization, as seen in Oregon and Colorado, establishes a regulated system for the production, distribution, and consumption of psilocybin, often with specific guidelines for therapeutic use. Decriminalization, on the other hand, typically removes criminal penalties for personal possession and use, often making it a low law enforcement priority, but the substance remains illegal under state law. It essentially reduces the severity of the offense, often to a civil infraction or no penalty at all, but the substance remains illegal under state law. This distinction is crucial for understanding the risks and protections afforded in different jurisdictions.
The Future of Psilocybin Legality
The trend towards greater acceptance and accessibility of psilocybin is expected to continue. More states are considering legislation to decriminalize or legalize psilocybin for medical or adult use. The ongoing research into psilocybin\\\'s therapeutic potential for conditions like depression, anxiety, and PTSD is also likely to influence policy decisions. As scientific evidence mounts and public perception shifts, the federal government may eventually be compelled to re-evaluate psilocybin\\\'s Schedule I status, potentially paving the way for broader access and integration into mainstream healthcare. This evolving landscape presents both opportunities and challenges for individuals and businesses in the psychedelic space, including brands like Shrooomz, which are committed to providing high-quality functional mushroom products and advocating for responsible access to psychedelics.
Historical Context: The Journey from Sacred Medicine to Schedule I
The history of psilocybin in the United States is a complex narrative, beginning with its traditional use as a sacred medicine by indigenous cultures for centuries [9]. In the mid-20th century, Western science began to explore its therapeutic potential, with promising research conducted in the 1950s and 1960s [10]. However, the rise of the counterculture movement and associated recreational use led to a societal backlash. In 1970, the Controlled Substances Act classified psilocybin as a Schedule I drug, effectively halting scientific research for decades [11]. This classification, based on perceived high abuse potential and lack of accepted medical use, has been increasingly challenged by modern research demonstrating its therapeutic benefits and relatively low risk profile [12].
Therapeutic Potential and Medical Exemptions
Beyond recreational or spiritual use, the most significant driver of psilocybin reform is its burgeoning therapeutic potential. Clinical trials have shown psilocybin to be effective in treating a range of mental health conditions, including treatment-resistant depression, major depressive disorder, anxiety, PTSD, and end-of-life distress [13]. The FDA\'s breakthrough therapy designations underscore the medical community\'s growing recognition of psilocybin as a promising treatment. In some states, like New Mexico, specific medical exemptions or acts have been passed to allow for the medical use of psilocybin under certain conditions, reflecting a growing divergence between federal and state approaches to medical access [14]. These medical pathways often involve strict regulations, including patient eligibility, licensed practitioners, and controlled environments, ensuring patient safety and therapeutic efficacy.
Navigating the Legal Landscape: Important Considerations
For individuals considering psilocybin, understanding the legal landscape is paramount. Even in states or cities where psilocybin is decriminalized or legalized for supervised use, federal law still technically prohibits its possession, cultivation, and distribution. This creates a complex legal gray area that individuals must navigate carefully. It is always advisable to consult with legal professionals familiar with psychedelic law in your specific jurisdiction. Furthermore, for those interested in the therapeutic benefits, seeking out licensed and regulated programs, such as those in Oregon and Colorado, provides the safest and most legally sound pathway to access. The responsible use of psilocybin, whether for personal growth or therapeutic purposes, is a core value promoted by organizations and brands like Secret Shrooomz, which advocates for informed decisions and adherence to evolving legal guidelines.
State-by-State Psilocybin Legal Status Overview
| State | Federal Status | State-Level Legalization | Decriminalization | Notes |
|---|---|---|---|---|
| Alabama | Schedule I | No | No | |
| Alaska | Schedule I | No | No | State law lists psilocybin as Schedule II. |
| Arizona | Schedule I | No | No | |
| Arkansas | Schedule I | No | No | |
| California | Schedule I | No | Yes (some cities) | Oakland and Santa Cruz have decriminalized natural psychedelics. |
| Colorado | Schedule I | Yes | Yes | Proposition 122 (2022) created regulated access to natural medicines and allows personal cultivation/sharing. |
| Connecticut | Schedule I | No | No | |
| Delaware | Schedule I | No | No | |
| District of Columbia | Schedule I | No | Yes | Initiative 81 (2020) decriminalized entheogenic plants and fungi. |
| Florida | Schedule I | No | No | |
| Georgia | Schedule I | No | No | |
| Hawaii | Schedule I | No | No | |
| Idaho | Schedule I | No | No | |
| Illinois | Schedule I | No | No | |
| Indiana | Schedule I | No | No | |
| Iowa | Schedule I | No | No | |
| Kansas | Schedule I | No | No | |
| Kentucky | Schedule I | No | No | |
| Louisiana | Schedule I | No | No | |
| Maine | Schedule I | No | No | State law lists psilocybin as Schedule X. |
| Maryland | Schedule I | No | No | |
| Massachusetts | Schedule I | No | No | |
| Michigan | Schedule I | No | Yes (some cities) | Ann Arbor and Detroit have decriminalized entheogenic plants. |
| Minnesota | Schedule I | No | No | |
| Mississippi | Schedule I | No | No | |
| Missouri | Schedule I | No | No | |
| Montana | Schedule I | No | No | |
| Nebraska | Schedule I | No | No | |
| Nevada | Schedule I | No | No | |
| New Hampshire | Schedule I | No | No | |
| New Jersey | Schedule I | No | No | |
| New Mexico | Schedule I | Yes (medical) | No | Medical Psilocybin Act exempts medical use. |
| New York | Schedule I | No | No | |
| North Carolina | Schedule I | No | No | |
| North Dakota | Schedule I | No | No | |
| Ohio | Schedule I | No | No | |
| Oklahoma | Schedule I | No | No | |
| Oregon | Schedule I | Yes | Yes | Measure 109 (2020) created a legal framework for supervised psilocybin therapy. |
| Pennsylvania | Schedule I | No | No | |
| Rhode Island | Schedule I | No | No | |
| South Carolina | Schedule I | No | No | |
| South Dakota | Schedule I | No | No | |
| Tennessee | Schedule I | No | No | |
| Texas | Schedule I | No | No | |
| Utah | Schedule I | No | No | |
| Vermont | Schedule I | No | No | State law lists psilocybin in a regulated drug rule. |
| Virginia | Schedule I | No | No | |
| Washington | Schedule I | No | Yes (some cities) | Seattle has decriminalized natural psychedelics. |
| West Virginia | Schedule I | No | No | |
| Wisconsin | Schedule I | No | No | |
| Wyoming | Schedule I | No | No | |
| American Samoa | Schedule I | No | No | |
| Guam | Schedule I | No | No | |
| Northern Mariana Islands | Schedule I | No | No | |
| Puerto Rico | Schedule I | No | No | |
| U.S. Virgin Islands | Schedule I | No | No |
Further Reading from Shrooomz
- Microdosing Mushrooms for Depression
- Psilocybin and PTSD Research
- How to Start Microdosing Psilocybin: A Science-Based Protocol
Frequently Asked Questions About Psilocybin Legality
Q: Is psilocybin legal at the federal level?
A: No, psilocybin remains a Schedule I controlled substance under federal law, meaning it is considered to have a high potential for abuse and no accepted medical use. However, federal enforcement for personal use is rare, and the FDA has granted breakthrough therapy designations for psilocybin research.
Q: What is the difference between decriminalization and legalization?
A: Decriminalization reduces or eliminates criminal penalties for personal possession and use, often making it a low law enforcement priority, but the substance remains illegal. Legalization, conversely, creates a regulated system for the production, distribution, and use of psilocybin, often with specific guidelines for therapeutic or adult use.
Q: Which states have legalized psilocybin?
A: As of 2026, Oregon and Colorado have established legal frameworks for supervised psilocybin services. Oregon through Measure 109 and Colorado through Proposition 122, both allow for regulated access to psilocybin in licensed settings.
Q: Can I grow psilocybin mushrooms for personal use?
A: In some jurisdictions, like Colorado under Proposition 122, personal cultivation and sharing (without remuneration) of psilocybin are permitted for adults 21 and over. However, this is not universally true, and federal law still prohibits cultivation. Always check local and state laws.
Q: What is the role of the FDA in psilocybin\\'s legal status?
A: The FDA has granted psilocybin breakthrough therapy designations for treatment-resistant depression and major depressive disorder, accelerating research and development. If psilocybin receives FDA approval for medical use, it would likely lead to a reevaluation and potential rescheduling of its federal status, significantly impacting its legality nationwide.
References
- Controlled Substances Act, 21 U.S.C. § 812.
- Drug Enforcement Administration. (n.d.). *Drugs of Abuse*. Retrieved from https://www.dea.gov/drug-information/drug-scheduling
- Psychedelic Alpha. (n.d.). *Psychedelics Legalization & Decriminalization Tracker*. Retrieved from https://psychedelicalpha.com/resources/psychedelic-laws/
- Food and Drug Administration. (2018, 2019). *Breakthrough Therapy Designations for Psilocybin*.
- May, H. (2025, July 20). *Synthetic Psilocybin Nears FDA Review, Signaling a Potential Shift in American Mental Healthcare*. CPR News. Retrieved from https://www.cpr.org/2025/07/20/synthetic-psilocybin-nears-fda-review/
- Oregon Health Authority. (n.d.). *Oregon Psilocybin Services*. Retrieved from https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Oregon-Psilocybin-Services.aspx
- Colorado Natural Medicine Health Act, Proposition 122. (2022).
- Legislative Analysis and Public Policy Association. (2025, November). *Psilocybin: Summary of State Laws*. Retrieved from https://legislativeanalysis.org/wp-content/uploads/2026/02/Psilocybin-Summary-of-State-Laws.pdf
- Johnson, M. W., & Griffiths, R. R. (2017). Potential Therapeutic Effects of Psilocybin. *Neurotherapeutics*, 14(3), 734-742.
- Ziff, S., et al. (2024). Analysis of Psilocybin-assisted Therapy in Medicine: A Narrative Review. *Cureus*, 14(2), e21944.
- Controlled Substances Act, 21 U.S.C. § 812.
- Marks, M. (2023). The Varieties of Psychedelic Law. *Neuropharmacology*, 266, 109399.
- Heal, D. J., et al. (2023). Psychedelics: Threshold of a Therapeutic Revolution. *Neuropharmacology*, 236, 109610.
- New Mexico Medical Psilocybin Act. (n.d.).
Ready to experience the difference?
Shop Secret Shrooomz →